ArticleInfection2026
Pathogen and host biomarkers to aid early diagnosis and prognosis of tuberculous meningitis.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculous meningitis (TBM) is the most sinister form of extrapulmonary tuberculosis (EPTB), associated with high mortality due to delayed diagnosis and limited sensitivity of conventional and molecular tests. Current study evaluated the diagnostic utility of Lipoarabinomannan antigen (LAM) detection in CSF and urine and explored host inflammatory biomarkers for diagnosis and prognosis of TBM.
methodsThis prospective observational cohort study enrolled 80 HIV-negative adults with presumptive TBM at a tertiary care center. Patients were classified according to the uniform TBM case definition, based on clinical, CSF, radiological, and microbiological findings. CSF samples were subjected to AFB microscopy, liquid culture (MGIT-960), GeneXpert MTB/RIF (GX), and LAM lateral flow assay. Urine LAM was performed at baseline. Serum and CSF levels of IL-1β, IL-6, TNF-α, IFN-γ, IL-17 A, and IP-10 were measured at baseline and after 1 month of treatment.
resultsAmong 80 HIV-negative participants, 23 (28.7%) had definite TBM and 46 (57.5%) had probable TBM. CSF LAM sensitivity and specificity against microbiological reference standards were 43.5% and 80.7%, while urine LAM sensitivity (60.9%) and specificity 82.5% were higher. Against composite reference standards, both CSF and urine LAM showed reduced sensitivity but achieved 100% specificity. Serum IL-1β demonstrated the highest diagnostic performance for distinguishing TBM from non-TBM patients (AUC 0.943; sensitivity 88.9%, specificity 90.9%). Elevated serum and CSF IP-10 levels were associated with on-treatment mortality, whereas declining IL-6 and TNF-α levels correlated with treatment response.
conclusionLAM detection in CSF and urine may serve as a useful adjunct to existing diagnostic approaches for TBM when interpreted alongside clinical, radiological, and microbiological findings. Host inflammatory biomarkers, especially IL-1β and IP-10, show additional diagnostic and prognostic value. Combining LAM testing with cytokine biomarkers may improve early diagnosis and efficient clinical management of TBM. However, larger multicentre studies are required to validate these findings before routine clinical implementation.
Indexed as
Identifiers
42848178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.